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Résumé en
anglais
The oral route is the most common route for drug delivery. However, oral
bioavailability is influenced by drug solubility and permeability. For drugs belonging to
the biopharmaceutical classification system class II, class III, and class IV, drug
encapsulation in nanocarriers provides an alternative solution to enhance
bioavailability. Lipid nanocapsules (LNCs) developed by our group, have proven to be
very interesting for the oral administration. These nanoparticles have a size that
ranges from 20 to 100 nm and are prepared by a well-known low energy emulsification
process: The phase-inversion temperature method. They have already shown promising
properties for the oral delivery of paclitaxel, Sn38, fondaparinux and miltefosine. LNCs
have demonstrated in vitro stability in simulated gastrointestinal media. They have also
shown their stability and diffusion in intestinal mucus. Furthermore, LNCs were taken
up by Caco-2 cells (intestinal cell model) mainly via active endocytosis. This active
transport was not size-dependent in the range investigated. Moreover, tight junctions
were not disrupted by LNCs and consequently the paracellular transport was not
possible. Additionally, these nanocarriers have demonstrated a direct effect of P-gp on
their endocytosis. Finally, LNCs have the ability to enhance the bioavailability of BCS
class IV drugs. Besides, another challenge of drug delivery via the oral route is to
target pharmacological receptors after absorption, like nanocarriers injected via the
intravenous route. For this purpose, it is important to design nanocarriers that are able
to be absorbed while keeping their integrity, and thus able to behave as circulating
nanocarriers. This lecture will show how LNCs allow enhancing oral bioavailibity of
drugs. Special attention will be paid to the ability of those LNCs to maintain their full
integrity after crossing a human epithelium model. For this purpose, two
complementary techniques were employed: Förster resonance energy transfer (FRET)
and nanoparticle tracking analysis (NTA).
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